Comparative Efficacy and Safety of GLP-1 Receptor Agonists for Weight Reduction: A Model-based Meta-analysis of Placebo-controlled Trials

Overview

Journal Obes Pillars

Date 2025 Feb 21

PMID 39980735

Authors

Haoyang Guo

Juan Yang

Jihan Huang

Ling Xu

Yinghua Lv

Yexuan Wang

Jiyuan Ren

Yulin Feng

Qingshan Zheng

Lujin Li

Affiliations

Soon will be listed here.

Abstract

Aim: Obesity is a global epidemic. The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity. Clinical trials of GLP-1/GIP/glucagon(GCG) triple agonists are ongoing. This study compared the efficacy and safety profiles of different GLP-1 receptor agonists (GLP-1RAs) for weight reduction and explored the related influencing factors, providing quantitative information for the development of GLP-1RAs and their clinical use.

Methods: This systematic review of public databases included placebo-controlled randomized clinical trials of GLP-1RAs. Time-course, dose-response, and covariate models were used to describe the efficacy characteristics and influencing factors of different GLP-1RAs. Subgroup analyses were performed to explore efficacy differences in receptor specificity. Meta-analyses compared the incidence of adverse event and dropout rates among different GLP-1RAs.

Results: Fifty-five studies involving 16,269 participants and 12 GLP-1RAs were included. Six drugs showed significant dose-response relationships. The maximum weight reduction effect ranged from 4.25 kg (Liraglutide) to 22.6 kg (Retatrutide). Reported onset times ranged from 6.4 weeks (Orforglipron) to 19.5 weeks (Tirzepatide). At 52 weeks, weight reduction effects were 7.03 kg, 11.07 kg, and 24.15 kg for mono-agonists, dual-agonists, and tri-agonists, respectively. There was a significant negative correlation in the exponential pattern between age and weight reduction effect, whereas baseline weight and BMI had no significant impact. Common adverse events of GLP-1RAs, reported in the literature include nausea, vomiting, diarrhea, and constipation, with a significantly higher incidence of nausea than that of placebo.

Conclusions: This study provides a quantitative evaluation of the efficacy and safety of GLP-1RAs and offers valuable insights into the assessment of new drugs for weight reduction.

References

Jackson V, Breen D, Fortin J, Liou A, Kuzmiski J, Loomis A . Latest approaches for the treatment of obesity. Expert Opin Drug Discov. 2015; 10(8):825-39. DOI: 10.1517/17460441.2015.1044966. View

Doggrell S . Retatrutide showing promise in obesity (and type 2 diabetes). Expert Opin Investig Drugs. 2023; 32(11):997-1001. DOI: 10.1080/13543784.2023.2283020. View

Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros C . Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023; 58:101882. PMC: 10041469. DOI: 10.1016/j.eclinm.2023.101882. View

Chao A, Tronieri J, Amaro A, Wadden T . Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2021; 33(3):159-166. PMC: 9209591. DOI: 10.1016/j.tcm.2021.12.008. View

Dubois-Laforgue D, Boutboul D, Levy D, Joly D, Timsit J . Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists. Diabetes Res Clin Pract. 2014; 103(3):e53-5. DOI: 10.1016/j.diabres.2013.11.014. View

Madsbad S, Kielgast U, Asmar M, Deacon C, Torekov S, Holst J . An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. Diabetes Obes Metab. 2011; 13(5):394-407. DOI: 10.1111/j.1463-1326.2011.01357.x. View

Meldrum D, Morris M, Gambone J . Obesity pandemic: causes, consequences, and solutions-but do we have the will?. Fertil Steril. 2017; 107(4):833-839. DOI: 10.1016/j.fertnstert.2017.02.104. View

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

Baggio L, Drucker D . Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2020; 46:101090. PMC: 8085566. DOI: 10.1016/j.molmet.2020.101090. View

10.

Apovian C, Aronne L, Bessesen D, McDonnell M, Murad M, Pagotto U . Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015; 100(2):342-62. DOI: 10.1210/jc.2014-3415. View

11.

Filippatos T, Panagiotopoulou T, Elisaf M . Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2015; 11(3-4):202-30. PMC: 5397288. DOI: 10.1900/RDS.2014.11.202. View

12.

Johnston C, Moreno J, Foreyt J . Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. Curr Atheroscler Rep. 2014; 16(12):457. PMC: 5321176. DOI: 10.1007/s11883-014-0457-6. View

13.

Rojo-Tirado M, Benito P, Atienza D, Rincon E, Calderon F . Effects of age, sex, and treatment on weight-loss dynamics in overweight people. Appl Physiol Nutr Metab. 2013; 38(9):967-76. DOI: 10.1139/apnm-2012-0441. View

14.

Sandoval D, DAlessio D . Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev. 2015; 95(2):513-48. DOI: 10.1152/physrev.00013.2014. View

15.

Meier J, Gallwitz B, Salmen S, Goetze O, Holst J, Schmidt W . Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88(6):2719-25. DOI: 10.1210/jc.2003-030049. View

16.

Morissette A, Mulvihill E . Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches. J Pharm Pharm Sci. 2024; 27:13065. PMC: 11186996. DOI: 10.3389/jpps.2024.13065. View

17.

Afshin A, Forouzanfar M, Reitsma M, Sur P, Estep K, Lee A . Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017; 377(1):13-27. PMC: 5477817. DOI: 10.1056/NEJMoa1614362. View

18.

Colman E . Food and Drug Administration's Obesity Drug Guidance Document: a short history. Circulation. 2012; 125(17):2156-64. DOI: 10.1161/CIRCULATIONAHA.111.028381. View

19.

Jura M, Kozak L . Obesity and related consequences to ageing. Age (Dordr). 2016; 38(1):23. PMC: 5005878. DOI: 10.1007/s11357-016-9884-3. View

20.

Williams E, Mesidor M, Winters K, Dubbert P, Wyatt S . Overweight and Obesity: Prevalence, Consequences, and Causes of a Growing Public Health Problem. Curr Obes Rep. 2015; 4(3):363-70. DOI: 10.1007/s13679-015-0169-4. View